دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Guarding the gate against hyperbilirubinaemia
Eryun Zhang, Wendong Huang
doi : 10.1136/gutjnl-2022-327532
March 2023 - Volume 72 - 3
Transcription factor p63, a member of the p53 family of tumour suppressors, regulates hepatic glucose metabolism
Gilles Mithieux
Measuring size of smaller colorectal polyps using a virtual scale function during endoscopies
Daniel von Renteln, Roupen Djinbachian, Melissa Zarandi-Nowroozi, Mahsa Taghiakbari
Activation of NOTCH signaling via DLL1 is mediated by APE1-redox-dependent NF-κB activation in oesophageal adenocarcinoma
Lei Chen, Heng Lu, Dunfa Peng, Long Long Cao, Farah Ballout, Kannappan Srirmajayam, Zheng Chen, Ajaz Bhat, Timothy C Wang, Anthony Capobianco, Jianwen Que, Oliver Gene McDonald, Alexander Zaika, Shutian Zhang, Wael El-Rifai
doi : 10.1136/gutjnl-2022-327076
Objective Oesophageal adenocarcinoma (EAC) arises in the setting of Barrett’s oesophagus, an intestinal metaplastic precursor lesion that can develop in patients with chronic GERD. Here, we investigated the role of acidic bile salts, the mimicry of reflux, in activation of NOTCH signaling in EAC.
Early management of acute severe UC in the biologics era: development and international validation of a prognostic clinical index to predict steroid response
Alex Adams, Vipin Gupta, Waled Mohsen, Thomas P Chapman, Deloshaan Subhaharan, Pradeep Kakkadasam Ramaswamy, Sudheer Kumar, Saurabh Kedia, Colleen GC McGregor, Tim Ambrose, Bruce D George, Rebecca Palmer, Oliver Brain, Alissa Walsh, Vineet Ahuja, Simon P L Travis, Jack Satsangi
doi : 10.1136/gutjnl-2022-327533
Objectives We aimed to determine whether changes in acute severe colitis (ASC) management have translated to improved outcomes and to develop a simple model predicting steroid non-response on admission.
Distinct blood protein profiles associated with the risk of short-term and mid/long-term clinical relapse in patients with Crohn’s disease stopping infliximab: when the remission state hides different types of residual disease activity
Nicolas Pierre, Vân Anh Huynh-Thu, Thomas Marichal, Matthieu Allez, Yoram Bouhnik, David Laharie, Arnaud Bourreille, Jean-Frédéric Colombel, Marie-Alice Meuwis, Edouard Louis
doi : 10.1136/gutjnl-2022-327321
Objective Despite being in sustained and stable remission, patients with Crohn’s disease (CD) stopping anti-tumour necrosis factor α (TNFα) show a high rate of relapse (~50% within 2 years). Characterising non-invasively the biological profiles of those patients is needed to better guide the decision of anti-TNFα withdrawal.
Postinfective bowel dysfunction following Campylobacter enteritis is characterised by reduced microbiota diversity and impaired microbiota recovery
Jonna Jalanka, David Gunn, Gulzar Singh, Shanthi Krishnasamy, Melanie Lingaya, Fiona Crispie, Laura Finnegan, Paul Cotter, Louise James, Adam Nowak, Giles Major, Robin C Spiller
doi : 10.1136/gutjnl-2021-326828
Objectives Persistent bowel dysfunction following gastroenteritis (postinfectious (PI)-BD) is well recognised, but the associated changes in microbiota remain unclear. Our aim was to define these changes after gastroenteritis caused by a single organism, Campylobacter jejuni, examining the dynamic changes in the microbiota and the impact of antibiotics.
Human gut microbiota after bariatric surgery alters intestinal morphology and glucose absorption in mice independently of obesity
Fernando F Anhê, Soumaya Zlitni, Song-Yang Zhang, Béatrice So-Yun Choi, Cassandra Y Chen, Kevin P Foley, Nicole G Barra, Michael G Surette, Laurent Biertho, Denis Richard, André Tchernof, Tony K T Lam, Andre Marette, Jonathan Schertzer
doi : 10.1136/gutjnl-2022-328185
Objective Bariatric surgery is an effective treatment for type 2 diabetes (T2D) that changes gut microbial composition. We determined whether the gut microbiota in humans after restrictive or malabsorptive bariatric surgery was sufficient to lower blood glucose.
Hepatic p63 regulates glucose metabolism by repressing SIRT1
Maria J Gonzalez-Rellan, Eva Novoa, Natalia da Silva Lima, Amaia Rodriguez, Christelle Veyrat-Durebex, Samuel Seoane, Begoña Porteiro, Marcos F Fondevila, Uxia Fernandez, Marta Varela-Rey, Ana Senra, Cristina Iglesias, Adriana Escudero, Miguel Fidalgo, Diana Guallar, Roman Perez-Fernandez, Vincent Prevot, Markus Schwaninger, Miguel López, Carlos Dieguez, Roberto Coppari, Gema Frühbeck, Ruben Nogueiras
doi : 10.1136/gutjnl-2021-326620
Objective p63 is a transcription factor within the p53 protein family that has key roles in development, differentiation and prevention of senescence, but its metabolic actions remain largely unknown. Herein, we investigated the physiological role of p63 in glucose metabolism.
Post COVID-19 irritable bowel syndrome
Giovanni Marasco, Cesare Cremon, Maria Raffaella Barbaro, Giulia Cacciari, Francesca Falangone, Anna Kagramanova, Dmitry Bordin, Vasile Drug, Egidia Miftode, Pietro Fusaroli, Salem Youssef Mohamed, Chiara Ricci, Massimo Bellini, Mohammed Masudur Rahman, Luigi Melcarne, Javier Santos, Beatriz Lobo, Serhat Bor, Suna Yapali, Deniz Akyol, Ferdane Pirincci Sapmaz, Yonca Yilmaz Urun, Tugce Eskazan, Altay Celebi, Huseyin Kacmaz, Berat Ebik, Hatice Cilem Binicier, Mehmet Sait Bugdayci, Munkhtsetseg Banzragch Yağcı, Husnu Pullukcu, Berrin Yalınbas Kaya, Ali Tureyen, İbrahim Hatemi, Elif Sitre Koc, Goktug Sirin, Ali Riza Calıskan, Goksel Bengi, Esra Ergun Alıs, Snezana Lukic, Meri Trajkovska, Keren Hod, Dan Dumitrascu, Antonello Pietrangelo, Elena Corradini, Magnus Simren, Jessica Sjölund, Navkiran Tornkvist, Uday C Ghoshal, Olga Kolokolnikova, Antonio Colecchia, Jordi Serra, Giovanni Maconi, Roberto De Giorgio, Silvio Danese, Piero Portincasa, Antonio Di Sabatino, Marcello Maggio, Elena Philippou, Yeong Yeh Lee, Daniele Salvi, Alessandro Venturi, Claudio Borghi, Marco Zoli, Paolo Gionchetti, Pierluigi Viale, Vincenzo Stanghellini, Giovanni Barbara
doi : 10.1136/gutjnl-2022-328483
Objectives The long-term consequences of COVID-19 infection on the gastrointestinal tract remain unclear. Here, we aimed to evaluate the prevalence of gastrointestinal symptoms and post-COVID-19 disorders of gut–brain interaction after hospitalisation for SARS-CoV-2 infection.
Production and possible reduction of greenhouse gases produced during GI endoscopy activity: a systematic review of available literature
Abhilash Perisetti, Madhav Desai, Michael J Bourke, Ian Penman, Alessandro Repici, Duvvur Nageshwar Reddy, Hisao Tajiri, Douglas K Rex, Cesare Hassan, Prateek Sharma
doi : 10.1136/gutjnl-2022-328369
Background and aims Greenhouse gases (GHGs) that trap heat in the atmosphere are composed of carbon dioxide (CO2), methane, nitrous oxide and fluorinated gases (synthetic hydrofluorocarbons, perfluorocarbons and nitrogen trifluoride). In the USA, the health sector accounts for 8.5% of total GHG emissions. The primary objective of this systematic review was to critically analyse the carbon emissions data from GI endoscopic activity.
Methionine deficiency facilitates antitumour immunity by altering m6A methylation of immune checkpoint transcripts
Ting Li, Yue-Tao Tan, Yan-Xing Chen, Xiao-Jun Zheng, Wen Wang, Kun Liao, Hai-Yu Mo, Junzhong Lin, Wei Yang, Hai-Long Piao, Rui-Hua Xu, Huai-Qiang Ju
doi : 10.1136/gutjnl-2022-326928
Objective Methionine metabolism is involved in a myriad of cellular functions, including methylation reactions and redox maintenance. Nevertheless, it remains unclear whether methionine metabolism, RNA methylation and antitumour immunity are molecularly intertwined.
Temporality of body mass index, blood tests, comorbidities and medication use as early markers for pancreatic ductal adenocarcinoma (PDAC): a nested case–control study
Pui San Tan, Cesar Garriga, Ashley Clift, Weiqi Liao, Martina Patone, Carol Coupland, Rachael Bashford-Rogers, Shivan Sivakumar, Julia Hippisley-Cox
doi : 10.1136/gutjnl-2021-326522
Objective Prior studies identified clinical factors associated with increased risk of pancreatic ductal adenocarcinoma (PDAC). However, little is known regarding their time-varying nature, which could inform earlier diagnosis. This study assessed temporality of body mass index (BMI), blood-based markers, comorbidities and medication use with PDAC risk .
Molecular heterogeneity and commonalities in pancreatic cancer precursors with gastric and intestinal phenotype
Sven-Thorsten Liffers, Laura Godfrey, Lisa Frohn, Lena Haeberle, Aslihan Yavas, Rita Vesce, Wolfgang Goering, Friederike V Opitz, Nickolas Stoecklein, Wolfram Trudo Knoefel, Anna Melissa Schlitter, Guenter Klöppel, Elisa Espinet, Andreas Trumpp, Jens T Siveke, Irene Esposito
doi : 10.1136/gutjnl-2021-326550
Objective Due to the limited number of modifiable risk factors, secondary prevention strategies based on early diagnosis represent the preferred route to improve the prognosis of pancreatic ductal adenocarcinoma (PDAC). Here, we provide a comparative morphogenetic analysis of PDAC precursors aiming at dissecting the process of carcinogenesis and tackling the heterogeneity of preinvasive lesions.
GATA4 and GATA6 loss-of-expression is associated with extinction of the classical programme and poor outcome in pancreatic ductal adenocarcinoma
Mónica P de Andrés, Richard J Jackson, Irene Felipe, Sladjana Zagorac, Christian Pilarsky, Anna Melissa Schlitter, Jaime Martinez de Villareal, Gun Ho Jang, Eithne Costello, Steve Gallinger, Paula Ghaneh, William Greenhalf, Thomas Knösel, Daniel H Palmer, Petra Ruemmele, Wilko Weichert, Markus Buechler, Thilo Hackert, John P Neoptolemos, Faiyaz Notta, Núria Malats, Paola Martinelli, Francisco X Real
doi : 10.1136/gutjnl-2021-325803
Objective GATA6 is a key regulator of the classical phenotype in pancreatic ductal adenocarcinoma (PDAC). Low GATA6 expression associates with poor patient outcome. GATA4 is the second most expressed GATA factor in the pancreas. We assessed whether, and how, GATA4 contributes to PDAC phenotype and analysed the association of expression with outcome and response to chemotherapy.
FOXA2 prevents hyperbilirubinaemia in acute liver failure by maintaining apical MRP2 expression
Sai Wang, Rilu Feng, Shan Shan Wang, Hui Liu, Chen Shao, Yujia Li, Frederik Link, Stefan Munker, Roman Liebe, Christoph Meyer, Elke Burgermeister, Matthias Ebert, Steven Dooley, Huiguo Ding, Honglei Weng
doi : 10.1136/gutjnl-2022-326987
Objective Multidrug resistance protein 2 (MRP2) is a bottleneck in bilirubin excretion. Its loss is sufficient to induce hyperbilirubinaemia, a prevailing characteristic of acute liver failure (ALF) that is closely associated with clinical outcome. This study scrutinises the transcriptional regulation of MRP2 under different pathophysiological conditions.
Inactivated genotype 1a, 2a and 3a HCV vaccine candidates induced broadly neutralising antibodies in mice
Garazi Pena Alzua, Anne Finne Pihl, Anna Offersgaard, Carlos Rene Duarte Hernandez, Zhe Duan, Shan Feng, Ulrik Fahnøe, Christina Sølund, Nina Weis, Mansun Law, Jannick C Prentoe, Jan Pravsgaard Christensen, Jens Bukh, Judith Margarete Gottwein
doi : 10.1136/gutjnl-2021-326323
Objective A prophylactic vaccine is needed to control the HCV epidemic, with genotypes 1–3 causing >80% of worldwide infections. Vaccine development is hampered by HCV heterogeneity, viral escape including protection of conserved neutralising epitopes and suboptimal efficacy of HCV cell culture systems. We developed cell culture-based inactivated genotype 1–3 HCV vaccine candidates to present natively folded envelope proteins to elicit neutralising antibodies.
Cardiovascular disease risk in paediatric and young adult non-alcoholic fatty liver disease
Tracey G Simon, Bjorn Roelstraete, Naim Alkhouri, Hannes Hagström, Johan Sundström, Jonas F Ludvigsson
doi : 10.1136/gutjnl-2022-328105
Objective Longitudinal evidence is lacking regarding the long-term risk of major adverse cardiovascular events (MACE) in children and young adults with non-alcoholic fatty liver disease (NAFLD).
Liver stiffness thresholds to predict disease progression and clinical outcomes in bridging fibrosis and cirrhosis
Rohit Loomba, Daniel Q. Huang, Arun J Sanyal, Quentin Mark Anstee, Michael Trauner, Eric J Lawitz, Dora Ding, Lily Ma, Catherine Jia, Andrew Billin, Ryan S Huss, Chuhan Chung, Zachary Goodman, Vincent Wai-Sun Wong, Takeshi Okanoue, Manuel Romero-Gómez, Manal F Abdelmalek, Andrew Muir, Nezam Afdhal, Jaime Bosch, Stephen Harrison, Zobair M Younossi, Robert P Myers
doi : 10.1136/gutjnl-2022-327777
Objective In retrospective studies, liver stiffness (LS) by vibration-controlled transient elastography (VCTE) is associated with the risk of liver decompensation in patients with non-alcoholic steatohepatitis (NASH), but prospective data in biopsy-confirmed cohorts with advanced fibrosis are limited. We aimed to establish thresholds for LS by VCTE that predict progression to cirrhosis among patients with bridging fibrosis and hepatic decompensation among patients with cirrhosis due to NASH.
Irritable bowel syndrome: treatment based on pathophysiology and biomarkers
Michael Camilleri, Guy Boeckxstaens
doi : 10.1136/gutjnl-2022-328515
Objective To appraise the evidence that pathophysiological mechanisms and individualised treatment directed at those mechanisms provide an alternative approach to the treatment of patients with irritable bowel syndrome (IBS).
Transcolonic endoscopic appendicectomy: a spectacular but unconvincing proposition
Shail Shah, Marius Taniel Paraoan
Over-the-scope clips versus standard treatment
Alan N Barkun, Loren Laine, Grigorios I Leontiadis, John R Saltzman
Genetically proxied ketohexokinase function and risk of colorectal cancer: a Mendelian randomisation study
Amée M Buziau, Philip J Law, Gabriella Blokland, Casper Schalkwijk, Jean Scheijen, Pomme Simons, Carla van der Kallen, Simone Eussen, Pieter C Dagnelie, Marleen van Greevenbroek, Richard S Houlston, Anke Wesselius, Molly Went, Coen Stehouwer, Martijn CGJ Brouwers
An unusual cause of colonic ulceration
Melissa Chew, Julien Dion Schulberg, Prithi Bhathal, Tom R Sutherland, Mayur Garg
Correction: PMO-29 Switching between infliximab biosimilars: experience from two inflammatory bowel disease centres
